Literature DB >> 23751287

High-sensitivity troponin T as a diagnostic tool for acute coronary syndrome in the real world: an observational study.

Catharina Borna1, Johan Thelin, Bertil Ohlin, David Erlinge, Ulf Ekelund.   

Abstract

BACKGROUND: The 2011 European Society of Cardiology guidelines state that acute coronary syndrome (ACS) may be excluded with a rapid 3 h high-sensitivity troponin T (HsTnT) sampling protocol. We aimed to evaluate the diagnostic and prognostic performance of HsTnT in patients with chest pain admitted with possible ACS in routine care.
METHODS: A total of 773 consecutive patients admitted for in-hospital care for chest pain suspicious of ACS were included retrospectively. HsTnT values at admission and at 3-4 and 6-7 h were analysed for diagnostic performance. In addition, prognostic performance towards a combined 60-day endpoint of ACS, nonelective revascularization or death of all causes was studied.
RESULTS: Twenty-three per cent of the patients had ACS during the hospital stay and 1.6% had an endpoint after discharge but within 60 days. The sensitivity of HsTnT for ACS at admission, 3-4 and 6-7 h was only 68, 79 and 81%, respectively. Sensitivity and negative predictive value for acute myocardial infarction alone were 80 and 93% on admission and 97 and 99% at 3-4 h. Among patients aged 75 years and older, 63% had a positive HsTnT on admission, but only 39% of these had an ACS during hospital stay.
CONCLUSION: Our data confirm that prolonged testing with HsTnT after 3-4 h does not improve diagnostic performance for ACS. However, although sensitivity for acute myocardial infarction was very good, sensitivity for ACS was insufficient to rule out ACS even at 6-7 h. Less than half of all recorded positive HsTnT were true positives. On the basis of these results, we find it unlikely that HsTnT has improved the diagnosis of ACS in the emergency care setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23751287     DOI: 10.1097/MEJ.0b013e328362a71b

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  6 in total

1.  Interpretation of positive troponin results among patients with and without myocardial infarction.

Authors:  Kristen M Tecson; William Arnold; Tyler Barrett; Robert Birkhahn; Lori B Daniels; Christopher DeFilippi; Gary Headden; W Frank Peacock; Michael Reed; Adam J Singer; Jeffrey M Schussler; Stephen Smith; Martin P Than; Peter A McCullough
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-01

2.  Anti-glioma action of aloe emodin: the role of ERK inhibition.

Authors:  S Mijatovic; D Maksimovic-Ivanic; J Radovic; Dj Miljkovic; Lj Harhaji; O Vuckovic; S Stosic-Grujicic; M Mostarica Stojkovic; V Trajkovic
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

3.  On- versus off-hour care for patients with non-ST-segment elevation myocardial infarction in Germany : Exemplary results within the chest pain unit concept.

Authors:  F Breuckmann; F Remberg; D Böse; J Waltenberger; D Fischer; T Rassaf
Journal:  Herz       Date:  2016-05-19       Impact factor: 1.443

4.  Diagnostic values of chest pain history, ECG, troponin and clinical gestalt in patients with chest pain and potential acute coronary syndrome assessed in the emergency department.

Authors:  Arash Mokhtari; Eric Dryver; Martin Söderholm; Ulf Ekelund
Journal:  Springerplus       Date:  2015-05-07

5.  Predictive role of high sensitivity troponin T within four hours from presentation of acute coronary syndrome in elderly patients.

Authors:  Catharina Borna; Katarina Lockman Frostred; Ulf Ekelund
Journal:  BMC Emerg Med       Date:  2016-01-04

6.  How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities.

Authors:  Dieter Fischer; Friederike Remberg; Dirk Böse; Michael Lichtenberg; Philipp Kümpers; Pia Lebiedz; Hermann-Joseph Pavenstädt; Johannes Waltenberger; Frank Breuckmann
Journal:  Eur J Med Res       Date:  2016-03-17       Impact factor: 2.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.